Related Experiment Videos
Predicting costs of stem-cell transplantation
1Department of Adult Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. stephanie_lee@dfci.harvard.edu
Summary
Identifying high-cost stem-cell transplantation patients before treatment is not feasible. However, preventing complications like infection can significantly reduce overall transplantation costs and offer economic benefits.
Area of Science:
- Hematology
- Transplantation Medicine
- Health Economics
Background:
- Stem-cell transplantation (SCT) involves significant healthcare costs.
- Limited data exist on predicting SCT costs based on patient characteristics or managing complication-related expenses.
Purpose of the Study:
- To determine if baseline patient data can predict high-cost SCT treatments.
- To estimate inpatient costs associated with specific SCT complications.
Main Methods:
- Retrospective analysis of inpatient costs and clinical data for 236 SCT patients.
- Multivariable linear regression to assess associations between baseline factors, clinical events, and hospitalization costs.
Main Results:
- Median initial inpatient costs: $55,500 (autologous) and $105,300 (allogeneic).
- Mismatched allogeneic donor and year of transplant predicted costs, but no baseline factors identified the highest-cost patients.
- Infection and death increased autologous costs; infection, VOD, aGVHD, and death increased allogeneic costs.
Conclusions:
- Pre-transplant identification of highest-cost patients was not achieved.
- Clinical complications are strongly associated with increased SCT costs.
- Interventions focused on complication prevention may yield substantial economic benefits.